| Quarterly Financials | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
Revenue  | 10 | 34 | 88 | 76 | 296 | 338 | 399 | 429 | 333 | 379 | 295 | 430 | 453 |
| Expenses | 80 | 105 | 173 | 76 | 233 | 263 | 351 | 244 | 242 | 269 | 280 | 336 | 330 |
| EBITDA | -70 | -71 | -85 | -0 | 64 | 76 | 48 | 185 | 91 | 110 | 15 | 94 | 123 |
| Operating Profit % | -800 % | -210 % | -207 % | -4 % | 20 % | 21 % | 11 % | 43 % | 26 % | 28 % | 4 % | 21 % | 27 % |
| Depreciation | 19 | 18 | 20 | 20 | 68 | 68 | 69 | 69 | 68 | 70 | 70 | 72 | 72 |
| Interest | 18 | 25 | 26 | 21 | 42 | 45 | 46 | 33 | 28 | 34 | 38 | 23 | 31 |
| Profit Before Tax | -107 | -114 | -130 | -40 | -47 | -38 | -67 | 83 | -4 | 6 | -93 | -0 | 20 |
| Tax | 0 | 0 | 0 | 0 | -41 | 5 | 2 | -16 | -4 | -5 | -4 | -5 | -5 |
| Net Profit | -107 | -114 | -130 | -40 | -6 | -42 | -69 | 99 | -0 | 11 | -89 | 5 | 25 |
| EPS in ₹ | 0.00 | -27.37 | -31.32 | -9.67 | -0.51 | -10.13 | -6.31 | 8.61 | -0.02 | 0.92 | -7.74 | 0.40 | 2.18 |
Onesource Specialty Pharma
Onesource Specialty Pharma
1,619.70
-68.60
(-4.06%)
Market Cap
18,569.18 Cr
PE Ratio
-397.16
Volume
4,30,272.00
Day High - Low
1,692.90 - 1,601.50
52W High-Low
2,026.50 - 1,057.00
Company has added their latest Transcript1 day ago
View
Key Fundamentals
Market Cap
18,569.18 Cr
EPS
-6.44
PE Ratio
-397.16
PB Ratio
3.31
Book Value
508.58
EBITDA
294.29
Dividend Yield
0.00 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
-0.29
Debt to Equity
0.21
Analyst Rating and Forecast
- By Refinitiv from4 analysts
Actual
Company News
View All News
OneSource Specialty Pharma Ltd reported a consolidated net profit of ₹292.97 million in Q1FY26, turning around from a loss of ₹26.84 million in the same period last year. Revenue rose 37% YoY to ₹4,490.23 million.
OneSource Specialty Pharma Limited disclosed changes in its Senior Management Personnel effective July 24, 2026. Ravi Kumar resigned, while Preeti Kalra was designated as SMP.
OneSource Q1FY27 earnings call on Jul 25
Jul 21, 2026
Jul 21, 2026OneSource Specialty Pharma Ltd will host an earnings call on July 25, 2026, to discuss unaudited Q1FY27 results. The call begins at 10:00 AM IST.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,990.50 | #1 4,77,587.63 | 41.71 | #1 61,673.90 | 12.69 | #1 11,565 | 25.80 | 66.37 | |
8,056.00 | 2,13,861.49 | 81.06 | 11,067.00 | 13.95 | 2,568 | 13.44 | 82.30 | |
5,122.80 | 1,94,854.84 | 86.65 | 13,886.20 | 20.34 | 2,138 | 3.28 | 64.10 | |
1,473.20 | 1,19,011.77 | 35.29 | 29,044.60 | 2.24 | 3,870 | -39.18 | 61.43 | |
1,126.80 | 1,13,382.45 | 21.72 | 27,657.90 | 17.64 | 5,026 | 7.82 | 53.10 | |
2,415.00 | 1,10,421.66 | #1 20.65 | 29,038.90 | #1 26.75 | 5,356 | 87.72 | 49.50 | |
2,469.60 | 1,01,993.49 | 51.48 | 14,636.40 | 14.85 | 1,938 | 29.13 | 44.89 | |
1,816.20 | 98,048.75 | 88.28 | 6,867.80 | 22.01 | 890 | #1 123.93 | 81.68 | |
1,148.10 | 95,828.36 | 30.00 | 35,058.60 | 3.90 | 4,158 | -69.10 | 28.48 | |
1,580.20 | 90,921.21 | 26.12 | 33,384.70 | 3.21 | 3,376 | 1.99 | 57.35 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
-2.78 %
Net Income Growth
444.34 %
Cash Flow Change
36.71 %
ROE
-99.69 %
ROCE
-103.78 %
EBITDA Margin (Avg.)
-38.10 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
| Total Assets | 972 | 1,258 | 2,442 | 2,009 | 1,309 | 7,550 | 8,210 |
| Fixed Assets | 354 | 633 | 1,231 | 1,361 | 863 | 6,118 | 2,719 |
| Current Assets | 25 | 99 | 511 | 228 | 176 | 1,086 | 1,426 |
| Capital Work in Progress | 543 | 431 | 490 | 335 | 188 | 218 | 314 |
| Investments | 0 | 0 | 0 | 5 | 20 | 16 | 439 |
| Other Assets | 75 | 195 | 722 | 309 | 238 | 1,199 | 0 |
| Total Equity & Liabilities | 972 | 1,258 | 2,442 | 2,009 | 1,309 | 7,550 | 8,210 |
| Current Liabilities | 194 | 161 | 809 | 865 | 631 | 1,114 | 1,442 |
| Non Current Liabilities | 361 | 321 | 621 | 358 | 282 | 556 | 937 |
| Total Equity | 417 | 776 | 1,013 | 786 | 396 | 5,881 | 5,831 |
| Reserve & Surplus | 414 | 775 | 1,009 | 781 | 392 | 5,869 | 5,820 |
| Share Capital | 1 | 2 | 3 | 4 | 4 | 11 | 12 |
Cash Flow
| Cash Flow | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 56 | 55 | -112 | 13 | 143 |
| Investing Activities | -207 | -692 | -68 | 511 | -201 |
| Operating Activities | -118 | -416 | -163 | -107 | -68 |
| Financing Activities | 381 | 1,162 | 118 | -391 | 412 |
Share Holding
| % Holding | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| Promoter | 37.77 % | 34.25 % | 29.79 % | 29.77 % | 29.93 % | 30.48 % | 30.48 % |
| FIIs | 17.44 % | 18.54 % | 18.69 % | 19.39 % | 19.24 % | 17.50 % | 19.19 % |
| DIIs | 12.56 % | 18.04 % | 18.10 % | 18.49 % | 18.81 % | 20.61 % | 23.38 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 13.05 % | 12.50 % | 13.25 % | 12.42 % | 12.39 % | 12.18 % | 11.29 % |
| Others | 19.18 % | 16.67 % | 20.17 % | 19.93 % | 19.63 % | 19.23 % | 15.65 % |
| No of Share Holders | 98,425 | 82,712 | 87,760 | 87,416 | 84,595 | 79,460 | 77,899 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 14 Feb 2024 |  Change Of Name | NA | 14 Feb 2024 | 0.00 | 0.00 |
| 29 Jan 2025 |  Quarterly Result Announcement | NA | 29 Jan 2025 | 0.00 | 1,536.60 |
| 05 May 2025 | Quarterly Result Announcement | NA | 05 May 2025 | 1,593.85 | 1,593.00 |
| 04 Aug 2025 | Quarterly Result Announcement | NA | 04 Aug 2025 | 1,995.05 | 1,847.80 |
| 22 Sept 2025 |  Annual General Meeting | NA | 22 Sept 2025 | 1,855.40 | 1,836.20 |
| 11 Nov 2025 | Quarterly Result Announcement | NA | 11 Nov 2025 | 1,825.85 | 1,790.90 |
| 23 Jan 2026 | Quarterly Result Announcement | NA | 23 Jan 2026 | 1,754.10 | 1,537.70 |
| 13 May 2026 | Quarterly Result Announcement | NA | 13 May 2026 | 1,742.70 | 1,833.55 |
| 24 Jul 2026 | Quarterly Result Announcement | NA | 24 Jul 2026 | 1,650.45 | 1,653.80 |
Announcements
Announcement under Regulation 30 (LODR)-Earnings Call Transcript1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Change in Management4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Allotment of ESOP / ESPS7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Change in Management7 days ago
7 days agoBoard Meeting Outcome for Intimation Of The Outcome Of The Board Meeting Dated July 24 2026 For The Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended June 30 20267 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 21, 2026
Jul 21, 2026Board Meeting Intimation for Approval Of The Unaudited Financial Results For The Quarter Ended June 30 2026.Jul 20, 2026
Jul 20, 2026Onesource Specialty Pharma And Formycon AG Announce
Strategic Manufacturing Partnership For BiosimilarsJul 14, 2026
Jul 14, 2026Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015Jul 09, 2026
Jul 09, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJul 08, 2026
Jul 08, 2026Completion Of US-FDA Inspection At Sterile Product Division (SPD) Facility At BengaluruJul 02, 2026
Jul 02, 2026Closure of Trading WindowJun 24, 2026
Jun 24, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 19, 2026
May 19, 2026General- UpdateMay 19, 2026
May 19, 2026General-UpdateMay 16, 2026
May 16, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 14, 2026
May 14, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 13, 2026
May 13, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 13, 2026
May 13, 2026Announcement under Regulation 30 (LODR)-Investor PresentationMay 13, 2026
May 13, 2026Update On Composite Scheme Of AmalgamationMay 13, 2026
May 13, 2026Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sMay 13, 2026
May 13, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMay 13, 2026
May 13, 2026Announcement under Regulation 30 (LODR)-Change in ManagementMay 13, 2026
May 13, 2026Board Meeting Outcome for Intimation Of The Outcome Of The Board Meeting Dated May 13 2026 For Approval Of The Standalone And Consolidated Financial Results For The Quarter And Year Ended March 31 2026May 13, 2026
May 13, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 07, 2026
May 07, 2026Board Meeting Intimation for Intimation Regarding Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015May 07, 2026
May 07, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 04, 2026
May 04, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 29, 2026
Apr 29, 2026General-UpdateApr 28, 2026
Apr 28, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 21, 2026
Apr 21, 2026Intimation Of "Renewal Of EU -GMP Certification For Onesource : Flagship Unit II FacilityApr 17, 2026
Apr 17, 2026Intimation Of ESG RatingApr 16, 2026
Apr 16, 2026Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSApr 09, 2026
Apr 09, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Apr 02, 2026
Apr 02, 2026Closure of Trading WindowMar 25, 2026
Mar 25, 2026Update On Composite Scheme Of ArrangementMar 06, 2026
Mar 06, 2026Announcement under Regulation 30 (LODR)-Credit RatingMar 05, 2026
Mar 05, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 04, 2026
Mar 04, 2026Intimation Regarding Receipt Of No Objection/ No Adverse Observation Letter From The National Stock Exchange Of India Limited / BSE Limited In Realation To The Draft Composite Scheme Of Arrangement And Amalgamation (Merger By Absorption).Feb 26, 2026
Feb 26, 2026Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 12, 2026
Feb 12, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 11, 2026
Feb 11, 2026Onesource Specialty Pharma Limited Has Informed The Exchange Regarding Disclosure Under Regulation 29(2) Of The SEBI (Substantial Acquisition Of Shares & Takeovers)Regulations 2011 And Regulation 7(2) Of SEBI (Prohibition Of Insider Trading) Regulations 2Feb 04, 2026
Feb 04, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 04, 2026
Feb 04, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 04, 2026
Feb 04, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 04, 2026
Feb 04, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 03, 2026
Feb 03, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Feb 03, 2026
Feb 03, 2026Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 52.38
ATR(14)
Volatile 70.21
STOCH(9,6)
Neutral 72.97
STOCH RSI(14)
Neutral 77.22
MACD(12,26)
Bullish 9.52
ADX(14)
Weak Trend 11.07
UO(9)
Bearish 61.79
ROC(12)
Uptrend And Accelerating 2.44
WillR(14)
Neutral -36.18
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
